Complement plays a role in both hepatic ischemia reperfusion (IR) injury (IRI) and liver regeneration, but it is not clear how complement is activated in either process. We investigated the role of self-reactive immunoglobulin M (IgM) antibodies in activating complement after hepatic IR and liver resection. Natural IgM antibodies that recognize danger-associated molecular patterns (neoepitopes) activate complement following both hepatic IR and liver resection. Antibody-deficient Rag1 -/-mice were protected from hepatic IRI, but had increased hepatic injury and an impaired regenerative response after 70% partial hepatectomy (PHx). We identified two IgM monoclonal antibodies (mAbs) that specifically reversed the effect of Rag1 deficiency in both models; B4 (recognizes Annexin IV) and C2 (recognizes subset of phospholipids). Focusing on the B4-specific response, we demonstrated sinusoidal colocalization of IgM and C3d in Rag1 -/-mice that were reconstituted with B4 mAb, and furthermore that the Annexin IV neoepitope is specifically and similarly expressed after both hepatic IR and PHx in wildtype (WT) mice. A single-chain antibody construct (scFv) derived from B4 mAb blocked IgM binding and reduced injury post-IR in WT mice, although, interestingly, B4scFv did not alter regeneration post-PHx, indicating that anti-Annexin IV antibodies are sufficient, but not necessary, for the regenerative response in the context of an entire natural antibody repertoire. We also demonstrated expression of the B4 neoepitope in postischemic human liver samples obtained posttransplantation and a corollary depletion in IgM recognizing the B4 and C2 neoepitopes in patient sera following liver transplantation. Conclusion: These data indicate an important role for IgM in hepatic IRI and regeneration, with a similar cross-species injury-specific recognition system that has implications for the design of neoepitope targeted therapeutics. (HEPATOLOGY 2018;67:721-735).
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A ctivation of the complement cascade is an integral part of both injury and recovery following a variety of hepatic insults, including hepatic ischemia reperfusion (IR) injury (IRI) and resection. However, it is not clear how complement is activated in the setting of either hepatic IR or resection.
Seminal studies demonstrated that natural immunoglobulin M (IgM) antibodies trigger complement activation upon ischemia and reperfusion of intestine (1, 2) and hindlimb. (3, 4) These natural antibodies bind to neoepitopes exposed on postischemic endothelium and lead to complement-dependent IRI. There is little known about Abbreviations: ALT, alanine aminotransferase; BrdU, 5-bromo-2 0 -deoxyuridine; DAB, 3,3 0 -diaminobenzidine; DAMPs, damage-associated molecular patterns; ELISA, enzyme-linked immunosorbent assay; FFP, fresh frozen plasma; FITC, fluorescein isothiocyanate; H&E, hematoxylin-eosin; IF, immunofluorescence; IgM, immunoglobulin M; IHC, immunohistochemistry; IL, interleukin; IR, ischemia reperfusion; IRB, institutional review board; IRI, ischemia reperfusion injury; LT, liver transplantation; mAb, monoclonal antibody; NP, 4-hydroxy-3-nitrophenylacetyl; PBS, phosphate-buffered saline; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PHx, partial hepatectomy; WT, wild type.
the role natural IgM antibodies play in hepatic injury and recovery, and indeed with regard to their role in hepatic IRI there are contradictory data (see Discussion). With regard to liver regeneration, although complement activation is essential for initiating the regenerative process, little is known concerning the complement activation trigger and whether IgM functions in a similar paradigm to IRI. It is known that IgM antibodies bind in the liver following partial hepatectomy (PHx), implicating them in the regenerative process, (5) but it has also been reported that antibody (Ab)-deficient Rag1 -/-mice have similar regeneration and injury profiles as wild-type (WT) mice post-PHx. (6) Pathogenic self-reactive antibody specificities have been identified using single-clone IgM antibody reconstitution studies done in antibody-deficient Rag1 -/-mice. CM22 monoclonal antibody (mAb), which binds to nonmuscle myosin and glycogen phosphorylase, was the first antibody identified to reconstitute IR injury in Rag1
-/-in a model of mesenteric IR. (2) Recently, other antibody specificities have been identified that can also reconstitute IRI in Rag1 -/-. These include B4 mAb, which binds to Annexin IV, an early marker of apoptotic cell death, (1) and C2 mAb, which recognizes a subset of phospholipids. (7) Importantly, it has been shown that blocking these antibodies by using antibody-specific peptides or proteins results in protection from IRI in WT mice, demonstrating that blockade of a single specificity is protective in the context of an entire natural antibody repertoire. (1, 3, 7, 8) These studies indicate the importance of these self-reactive antibodies in causing tissue injury and mark them as potential targets for therapeutic intervention. To this end, however, further research is needed to determine the extent of homology in antigen expression between organs, as well as similarities in antigen expression and antibody repertoires between mice and humans. With this in mind, the aim of the current study is to investigate the role of self-reactive antibodies in both liver IRI and regeneration.
Materials and Methods
Information of animals, surgical procedures, and liver functional assay are provided online in the Supporting Information.
IgM AND scFv PURIFICATION AND TREATMENT
C2 and B4 IgM mAbs were derived from hybridomas created by the fusion of C57BL/6 splenocytes with SP2/0-AG14 myeloma cells, and the resulting hybridomas were screened for binding to apoptotic cells.
(1) Those with positivity to apoptotic cells were further characterized to determine their exact specificities. The previous characterization of the binding specificity of theI gM mAbs by enzyme-linked immunosorbent assay (ELISA) demonstrated that C2 was specific for a subset of phospholipids (7) and that B4 was specific for posttranslationally modified Annexin IV, respectively, as described.
(1) F632 IgM mAb, used as an isotype control, was expressed by a hybridoma isolated from mice immunized with 4-hydroxy-3-nitrophenylacetyl (NP)-KLH and screened against NP-BSA. This control mAb was characterized previously in a cardiac transplant model. (9) Purification of mAbs was performed as described. reconstitution studies, Rag1 -/-mice were injected intravenously with mAbs (25 lg) immediately following either IR or PHx. Cloning and expression of B4 scFv in CHO cells was previously as described. (9) For therapeutic studies, WT mice were injected intravenously with B4 scFv (20 lg) 5 minutes before reperfusion or PHx.
LEVELS OF NATURAL IgM AND ALBUMIN IN HUMAN AND MOUSE SERUM
ELISAs for phosphatidylethanolamine (PE; SigmaAldrich), phosphatidylcholine (PC; Biosearch Technologies, Inc., Novato, CA), and Annexin IV (purified as described (1) ) were used to determine levels of specific natural IgM antibodies in human and mouse serum. Human serum was collected from 13 patients undergoing a liver transplantation (LT) at three time points; just before reperfusion, 1 hour postreperfusion, and 24 hours postreperfusion. Mouse serum was collected from sham-or IR-operated mice 6 hours postreperfusion. Phospholipid and Annexin IV ELISAs were performed as described. (7) Total IgM in human and mouse serum was measured by ELISA according to the manufacturer's instructions (Bethyl Laboratories, Montgomery, TX). Serum levels of albumin were measured using a colorimetric assay according to the manufacturer's instructions (Pointe Scientific INC).
HISTOLOGICAL ANALYSIS
For histological examination, tissue blocks were placed in 10% buffered formaldehyde solution for 48 hours before being embedded in paraffin. Liver histology was assessed by light microscopy (Olympus BH -2) of hematoxylin-eosin (H&E)-stained 4-lm sections in a blinded fashion on a semiquantitative scale. Ten random fields on each slide were assessed for necrosis of the parenchymal area by standard morphological criteria (loss of architecture, vacuolization, karyolysis, and increased eosinophilia), and the extent of necrosis was semiquantitatively estimated by assigning a severity score on a scale of 0-4 as described (10) (absent, 0; mild, 1; moderate, 2; severe, 3; and total necrotic destruction of the liver, 4).
ASSESSMENT OF LIVER REGENERATION
Mice were injected with 5-bromo-2 0 -deoxyuridine (BrdU; 50 mg/kg, intraperitoneally) 2 hours before being killed, and incorporation of BrdU was visualized by immunohistochemistry (IHC) using an anti-BrdU antibody (AbCam, Cambridge, MA) as described. (11) Restitution of liver weight is expressed as percentage of regenerated liver mass relative to total liver weight. Residual liver weight was calculated with the following equation: ([B (C A)]/B)*100, where A is the weight of the resected liver (30% of total liver), B is the estimated total liver weight based on the weight of the resected liver (B 5 A/0.7), and C is the final liver weight at the time of being killed. There was no significant difference in the liver to body weight ratios in WT versus Rag1 -/-mice used in the studies (liver/body weight for WT 5 0.51 6 0.02; Rag1 -/-5 0.049 6 0.03). Mitotic index was calculated by tallying the percentage of hepatocytes undergoing mitosis in 10 high-power fields on tissue sections stained with H&E. For reconstitution of Rag1 -/-mice with C5a (CompTech, Tyler, TX), the peptide was administered by intraperitoneal injection at 15 ug/ mouse/injection, with one dose given immediately before PHx, and again at 6 and 12 hours post-PHx, as described. (12) 
IHC AND IMMUNOFLUORESCENCE
Paraffin or frozen sections were cut at 4lm for IHC and immunofluorescence (IF) respectively. IHC sections were deparaffinized and antigen retrieval was performed using proteinase K (Vector Labs, Burlingame, CA). Frozen sections were fixed in acetone for 6 minutes and then air dried and equilibrated in phosphate-buffered saline (PBS). C3d deposition was detected using a goat antimouse C3d (1:20; R&D Systems, Minneapolis, MN), and IgM binding in mouse and human tissues was detected using a goat antimouse IgM (1:50; Sigma-Aldrich, St. Louis, MO) and rabbit antihuman IgM (1:1,000; Sigma-Aldrich, Billerica, MA) or antimouse IgM-FITC (fluorescein isothiocyanate) for IF (1:50; Millipore), human endothelial cells were detected using anti-human CD31-FITC (1:25; Abcam), and Annexin IV on human liver biopsies was detected using mouse B4 mAb (5 lg/mL; prepared as described above). For IHC, primary antibodies were detected using goat-IMMpress or rabbit-IMMpress kits (Vector Labs, Burlingame, CA). For IF, primary antibodies were detected using antigoat IgG Alexa Fluor-555 conjugate (1:200; Invitrogen, Carlsbad, CA) or antimouse IgM Alexa Fluor-555 conjugate (1:200; Invitrogen). Quantification of IHC staining was accomplished using automated image filters to extract 3,3 0 -diaminobenzidine (DAB) signal using appropriate negative and positive controls. Signal intensity was then computed per pixel, and average intensity per pixel was computed. All analyses were done using automatic scripts in MATLAB (The MathWorks, Inc., Natick, MA), and all images were analyzed as a batch using the same settings. Quantification of fluorescence for C3d and IgM deposition in human samples was done using an automated procedure that measured the average signal intensity per pixel on 403 fields using NIH ImageJ. Data are reported as intensity per pixel.
HUMAN SAMPLE ANALYSIS
All tissue samples and sera were collected as part of an approved institutional review board (IRB). For analysis of B4 mAb binding to human samples, liver biopsies were obtained from human ischemic donor livers before transplantation and postreperfusion, and "normal" liver samples were taken from areas of normal pathology following resection of hepatic hemangioma. Samples taken prereperfusion and postreperfusion were also analyzed for IgM and C3d deposition, as described above. Information on donors, ischemia time, and sample analysis are provided in Supporting  Table S1 . All samples were stored at -808C until analyzed. Samples were cut into 8-lM sections, washed, and permeabilized before blocking with serum-free protein block. Sections were then incubated with B4 mAb or control F632 mAb (5 ng/uL), washed, and incubated with horseradish peroxidase-conjugated antimouse IgM (1:200; Sigma-Aldrich). Signal was developed using DAB. All sections were imaged on an Olympus BX61 Microscope Light microscope with Visiopharm Acquisition Software. IgM and C3d deposition was analyzed by IF and quantified, as described above. Serum samples were analyzed as described below. Data on donor and recipient organs were part of our transplant and resection databases, and analysis was a part of our institutional approved IRB.
BIODISTRIBUTION STUDY
A B4 scFv biodistribution study was performed as we have described. (13) Briefly, B4 scFv was radiolabeled with 125
Iodine (New England Nuclear Corp.) using Peirce Iodination Reagent according to the manufacturer's instructions (Thermo Scientific), and 5 mCi was used to label 100 lg of B4scFv. Rag1 -/-mice were injected by the tail vein with 2 lg of radiolabeled protein immediately following IR, 70% Phx, or sham surgery, and animals were killed 6 hours postsurgery. Blood was removed by cardiac puncture and animals were perfused with PBS before the heart, brain, liver, intestine, lung, kidney, and spleen were removed. Tissues were rinsed with PBS, shredded, weighed, and then radioactivity was measured with a Hewlett-Packard 5780 c counter.
Results were recorded as lCi/g of tissue.
STATISTICAL ANALYSIS
Statistical analysis was performed using GraphPad Prism software (version 5.0; GraphPad Software Inc., La Jolla, CA. Statistical significance between multiple groups was assessed using analysis of variance. Student t test or Mann-Whitney U test was used to determine statistical significance between any two groups. A P value <0.05 was considered significant.
Results

IgM MONOCLONAL ANTIBODIES RECONSTITUTE HEPATIC IRI IN Rag1
-/-MICE Compared to WT mice, Rag1 -/-mice subjected to 30 minutes of total warm hepatic ischemia followed by 6 hours of reperfusion were protected from hepatic IRI, as demonstrated by significantly lower serum alanine aminotransferase (ALT) levels and histology scores ( Fig. 1 and Supporting Fig. S1 ). To confirm the role of natural self-reactive IgM in propagating hepatic IRI, antibodydeficient Rag1 -/-mice were reconstituted with one of two self-reactive IgM mAbs. These mAbs, isolated from unmanipulated WT C57BL/6 mice and termed B4 and C2, have been characterized and shown to recognize modified Annexin IV (B4) (1) and a subset of phospholipids (C2).
(7) Both B4 and C2 mAb restored injury levels in Rag1 -/-mice close to that observed in WT mice.
Reconstitution of Rag1
-/-mice with control F632 IgM mAb had no effect on hepatic IRI (Fig. 1) . Thus, single IgM mAbs of different specificities are sufficient to propagate hepatic IRI in antibody-deficient mice.
SELF-REACTIVE IgM ANTIBODIES ALSO PLAY AN IMPORTANT ROLE IN LIVER REGENERATION
Rag1
-/-mice have a diminished regenerative response following PHx (14) for incompletely understood reasons. To investigate the role of natural IgM antibodies in liver regeneration, we reconstituted Rag1 -/-mice with either B4 or C2 mAb after 70% PHx. Rag1 -/-mice had significantly increased injury and a significantly decreased regenerative response following 70% PHx, and reconstitution of Rag1 -/-mice with either B4 or C2 mAb, but not control F632 mAb, protected liver from injury as determined by histology score and serum ALT ( Fig. 2A,B and Supporting Fig. S2 ). Both B4 and C2 mAbs also restored regeneration to levels not significantly different to that observed in WT mice, as determined by BrdU incorporation, mitotic index, and liver weight restitution (Fig. 2C,D) . Thus, single IgM mAbs of different specificities are sufficient to stimulate the regenerative response following hepatic resection. Because there was a trend for increased restoration of injury/protection with B4 mAb compared to C2 mAb, we focused on the B4 mAb in subsequent studies.
The complement activation products C3a and/or C5a play a key role in in liver regeneration through their effect on cell-signaling processes involved in hepatocyte proliferation. (12) And although not previously studied in the context of hepatic IR or resection, IRI in other organs is promoted by IgM-mediated activation of complement (reviewed in Zhang and Carroll (15) ). We therefore investigated whether the basis for the impaired regenerative response post-PHx in Rag1
-/-mice may be attributed to the lack of IgMmediated complement activation, as opposed to the result of tissue injury induced by PHx in Rag1 -/-mice.
Reconstitution of Rag1
-/-mice post-PHx with C5a peptide reduced injury and enhanced the regenerative response (Fig. 2F,G and Supporting Fig. S3 ). These data, together with additional data on complement activation described below, indicate that an important component of the impaired regenerative response in Rag1 -/-mice is attributed to lack of complement activation and anaphylatoxin (C3a/C5a) generation.
SERUM IgM ANTIBODIES AND B4 mAb LOCALIZE TO INJURED TISSUE AND ACTIVATE COMPLEMENT
Hepatic deposition of IgM occurs following hepatic IRI (16, 17) and resection. (5) To investigate the relationship between IgM deposition and complement activation, and in particular a role for postischemia and postresection expression and recognition of the B4 (Annexin IV) neoepitope, we analyzed IgM and complement activation (indicated by C3d deposition) after either hepatic IR or 70% PHx. Following hepatic IR, IgM and C3d deposition was observed in an overlapping sinusoidal pattern in livers from WT mice and Rag1 -/-mice reconstituted with B4 mAb, but not in control-treated Rag -/-mice (Fig. 3A) . Similarly, following PHx, sinusoidal staining of both IgM and C3d was observed in WT mice and in Rag1 -/-mice -/-mice. Antibodies were given intravenously immediately after reperfusion and all measurements were taken at 6 hours postreperfusion. (A) Histological quantification of necrosis and injury, determined on a scale of 0-4. Representative H&E-stained sections are shown in Supporting Fig. S1 . (B) Serum ALT levels. Results expressed as mean 6 SEM, n 5 6. ***P < 0.001; **P < 0.01: *P < 0.05.
reconstituted with B4, but not in control-treated Rag1 -/-mice (Fig. 3B) -/-mice with B4 or C2 mAbs, but not control F632 mAb, was protective and restored regeneration to levels observed in WT mice. Antibodies were given intravenously immediately following 70% PHx, and injury and regeneration was assessed at 48 hours postsurgery. Hepatic injury was decreased in B4 and C2 reconsti- -/-mice that underwent 70% PHx with C5a peptide decreased liver injury as determined by (F) histological injury (representative H&E-stained sections are shown in Supporting Fig. S3 ), (G) BrdU incorporation, detected immunohistologically and expressed as % positives cell counted in 10 hpf, and (H) liver weight restitution. Results expressed as mean 6 SEM, n 5 5-6. ***P < 0.001; **P < 0.01; *P < 0.05. Abbreviation: hpf, high-power field. and postresection neoepitope. Thus, the Annexin IV neoepitope recognized by B4 mAb may represent a therapeutic target for the design of biologically based pharmacuticals aimed at either inhibiting hepatic IRI or to promoting liver regeneration.
CHARACTERIZATION OF A SINGLE-CHAIN ANTIBODY DERIVED FROM B4 IgM mAb
Although the data above indicate an important role for IgM antibodies in both hepatic IRI and liver regeneration, other studies done using Rag1 -/-mice have indicated a key role for T cells in hepatic IRI and regeneration. (6, 14, (17) (18) (19) Given the potential confounders and limitation of studies done in genetically engineered mice, we sought to confirm the role of natural Abs, and specifically Annexin IV-specific antibodies, using a WT mouse model and a B4scFv shown to competitively inhibit B4 mAb binding. (9) We first confirmed that B4 scFv localizes to the liver following either hepatic IR or 70% PHx by injecting 125 I-labeled B4 scFv immediately after surgery and measuring tissue distribution of radiolabel 6 hours after injection. Although still present in the circulation, 125 I-B4 scFv localized preferentially to the liver following hepatic IR or 70% PHx (Fig. 4) . A similar biodistribution after IRI and 70% PHx was obtained with the parent 125 
I-labeled B4 IgM mAb (not shown). Data above show that reconstitution of Rag1
-/-mice with a single IgM mAb was sufficient to restore injury following hepatic IR, and to determine whether interfering with the binding of IgM of single specificity would protect against IRI in the context of an entire natural Ab repertoire, we treated WT mice with B4 scFv following hepatic IR. Compared to PBS-treated controls, B4 scFv treatment protected against hepatic IRI as determined by serum ALT and histological score (Fig. 5A,B and Supporting Fig. S4 ). However, whereas B4 mAb reconstitution in Rag1 -/-mice restored regenerative capacity following PhX, treatment of WT mice with B4 scFv following Phx had no effect, and there was no difference in regenerative outcomes between PBS-and B4 scFv-treated mice (Fig.  5C,D and Supporting Fig. S5 ). The ability of B4 scFv to protect against IRI without impairing regeneration points toward the therapeutic potential of B4 scFv, or the use of B4 scFv as a targeting vehicle for therapeutics, in clinical settings such as liver resection or transplantation.
HEPATIC HUMAN ISCHEMIC TISSUE EXPRESSES B4 ANTIGEN
To examine the translational potential of B4 scFv or of a B4 scFv targeting strategy, we investigated expression of the B4 epitope in human postischemic tissue. Liver biopsies were obtained from ischemic human donor livers before transplantation. Sections stained positive for Annexin IV expression using B4 mAb, with a similar sinusoidal pattern of deposition to that observed in postischemic mouse liver sections (Fig.  6A) . The low signal observed with control F632 IgM mAb was similar to that observed with secondary Ab alone (data not shown). B4 mAb did not bind to biopsy sections taken from areas of normal pathology obtained from resections for hepatic hemangioma. These data demonstrate specific binding of B4 mAb to postischemic human livers.
FIG. 5.
Treatment with B4 scFv limits injury following hepatic ischemia reperfusion injury and does not alter liver recovery or regeneration following 70% PHx in WT mice. WT mice treated with B4 scFv had decreased hepatic injury compared to PBS-treated controls. WT mice underwent 30 minutes of ischemia followed by 6 hours of reperfusion. B4 scFv (20 lg) and PBS were administered intraperitoneally 5 minutes before reperfusion. Hepatic injury was measured by (A) histological quantification of necrosis and injury, determined on a scale of 0-4. Representative H&E-stained sections are shown in Supporting Fig. S4. (B) Serum ALT. Results expressed as mean 6 SEM, n 5 4-6. *P < 0.05. Following 70% PHx, WT mice treated with B4 scFv (20 lg) and PBS controltreated mice had similar injury and regeneration outcomes. All measures were made at 48 hours post-PHx. B4 scFv and PBS were administered intraperitoneally 5 minutes before PHx surgery. Following 70% PHx, liver injury was determined by (C) histological quantification of necrosis and injury, determined on a scale of 0-4. Representative H&E-stained sections are shown in Supporting 
SERUM LEVELS OF NATURAL IgM ARE DECREASED IN HUMAN LT RECIPIENTS
To further investigate whether a similar B4 recognition system occurs in humans, we investigated the level of anti-Annexin IV IgM Abs in serum from 13 patients pre-LT and post-LT. We additionally investigated levels of anti-PC and anti-PE IgM in patient serum, two phospholipids recognized by the C2 mAb (7) that also restores hepatic IRI in Rag1 -/-mice (above). Serial serum samples were taken from patients undergoing LT at three time points: just before transplantation (baseline) and at 1 and 24 hours after transplantation. Analysis by ELISA revealed that serum levels of IgM specific for Annexin IV were significantly decreased at 1 and 24 hours posttransplantation compared to levels of albumin, a serum protein used to control for dilutional effect of infusion of blood products given during surgery. Serum levels of IgM specific for PC were also significantly decreased at 1 and 24 hours posttransplantation. The decrease in anti-PE levels did not reach significance, although the decrease would be significant with the exclusion of data from 2 patients exhibiting an extremely high increase in anti-PE levels (Fig. 6B) . Total IgM was also significantly decreased at 1 and 24 hours posttransplantation.
Patients received an average of 15 units of packed red blood cells (range, 3-32), 4 units of platelets (range, 0-11), and 22 units of fresh frozen plasma (FFP; range, 4-48). However, it is unlikely that the decrease in serum IgM is attributed entirely to a dilutional effect for several reasons; most important, no correlation was observed between amount of blood products given and percentage change of IgM. If the decrease in serum IgM following transplantation was attributed to a dilutional effect, a positive correlation between amount of blood products given and precent change in IgM levels would be expected, which was not the case for any of the antigens measured (data not shown). Because of this lack of correlation, as well as no depletion of anti-PE IgM and the unique response observed in each patient (on a patient-to-patient level, the degree of antibody depletion was not consistent across specificities), the data suggest that anti-Annexin IV and anti-PC IgM are specifically removed from the circulation post-LT.
To correlate depletion of IgM from human serum with IgM deposition in the postischemic liver, we analyzed IgM and C3d deposition in transplanted human livers before and after reperfusion. Little to no IgM or C3d was detected in livers before reperfusion, but in postischemic and reperfused livers, high levels of bound IgM and C3d were observed in a characteristic sinusoidal pattern (Fig. 6C) .
To further support the above conclusion, we performed an analogous study using our mouse model of hepatic IRI that lacks many of the confounding conditions that are unavoidable in human LT, such as the infusion of blood products and genetic variability. Following hepatic IR in mice, serum levels of antiAnnexin IV IgM and total IgM were significantly decreased as compared to sham animals. Of the two C2 mAb antigens examined, levels of anti-PE were significantly decreased, whereas levels of anti-PC were unchanged, which was different to that observed in human serum post-LT (Fig. 7) . These data suggest that following both human and murine hepatic IR, IgM specific for Annexin IV is depleted from the circulation. The data further suggest that there may be differences in phospholipid subsets that represent postischemic neoepitopes expressed in mice and humans, although the C2 mAb, that recognizes both PC and PE (and some additional phospholipids), recognizes postischemic neoepitopes from both species. (7) Regarding the reduction in levels of total IgM observed post-IR, there are several specificities for natural pathogenic self-reactive antibodies, other than the two under study here. It has been estimated that the majority of circulating IgM is natural IgM, (20) and this likely accounts for the reduction in total circulating IgM post-IR.
Discussion
It has been shown that complement activation products are essential for eliciting hepatic IRI and also for initiating liver regeneration following PHx or toxic injury. (11, 12, 21) Seminal studies demonstrated that natural IgM antibodies activate complement following IR of the intestine (1) and skeletal muscle. (3, 4) Here, we demonstrate that IgM antibodies are also responsible for activating complement following hepatic IRI as well as PHx. The IgM mAbs used in this study, B4 and C2, recognize antigens uniquely expressed on stressed or damaged cells.
(1,7) However, although natural antibodies in general are known to play an important role in innate immunity to infection as well as homeostasis, B4 and C2 have only been investigated in the context of sterile inflammation, and only a pathogenic role for these antibodies has been described.
Here, we demonstrate a pathogenic role for these mAbs in liver injury, but additionally demonstrate that antigens recognized by these mAbs are also expressed following liver resection and are involved in the recovery process.
With regard to IRI, we found that both B4 and C2 mAbs activate complement and induce hepatic IRI in otherwise protected Rag1 -/-mice, respectively implicating Annexin IV and a subset of phospholipids as damage-associated molecular patterns (DAMPs) expressed in the postischemic liver. In addition, we demonstrated that B4 scFv protected against hepatic IRI in WT mice that contained a full natural Ab repertoire. It is interesting that although a diverse set of neoepitopes are exposed following IRI, blocking a single specificity is sufficient to prevent injury. Although this phenomenon has been described in other models of IRI, the physiology is not understood. It has been speculated by Kulik et al. (1) that there may be a sequential exposure of antigens that are recognized by IgM and activate complement, and that blockade of one antigen disrupts this order and prevents maximal complement activation. Alternatively, antigens recognized by pathogenic IgM Abs may be specific to a certain cell type and multiple cell types needed to be involved for IRI to occur, and therefore blocking one antigen could prevent injury to a specific subset of cells and subsequently ameliorate IRI. These theories suggest that recognition of multiple antigen specificities needs to occur in some sort of organized fashion in order to induce IRI. However, studies done in Rag1 -/-mice would imply that this is unlikely given that a single mAb can induce IRI in these mice. Another possible explanation for why a single antibody specificity can be sufficient for inducing IRI may be related to the redundant nature of the innate immune response. Natural IgM Abs are effectors of the innate immune response and as such are part of the DAMP recognition system. Many other effector molecules of the innate immune system similarly recognize DAMPs, some of which can also directly activate complement. For example, phospholipids and apoptotic cells recognized by B4 and C2 mAbs are also recognized by Tolllike receptor 4, (22) C-reactive protein, (23) and mannose-binding lectin. (24) Thus, it is possible that blocking one antigen limits multiple pathways in the innate DAMP recognition system, leading to a more robust inhibitory effect. Additionally, the inflammatory cascade does not progress linearly, but rather gets exponentially amplified as more components become involved, and blocking a small subset of antigens early in the injury process may have amplified effects on limiting subsequent damage.
Although a role for IgM in IRI of various organs has been described, the role of IgM in liver recovery following resection has not been directly addressed. Recent studies suggested a role for IgM in liver regeneration in a positive feedback loop involving complement activation and interleukin (IL)-4 upregulation, (5) but there was no direct evidence of complement activation by IgM following PHx, and whether IgM is necessary for regeneration was not investigated. We show that following PHx, IgM and C3d deposit in the remnant liver in an overlapping sinusoidal pattern in both WT mice and B4 mAb reconstituted Rag1
-/-mice, and that C3 deposition is absent in Rag1 -/-mice, strongly suggesting that IgM is activating complement in the setting of PHx. We also report that Rag1 -/-mice have increased injury and diminished regenerative response following PHx, and reconstitution with either B4 or C2 mAb (but not a control IgM mAb) is sufficient to restore regeneration to levels in WT mice. Our finding of increased injury and impaired regeneration after PHx in Rag1 -/-mice is contradictory to an earlier report that showed Rag1 -/-had similar injury and regeneration as WT mice following PHx. (6) We have no explanation for this difference because the mice used and model are the same. On the other hand, a study done by Tumanov et al. (14) showed similar results to ours in that Rag1 -/-had increased injury and decreased regeneration, although they found that reconstitution of Tcell-derived lymphotoxin restored regeneration in these mice, implicating a critical role for T cells in regeneration.
Overlapping roles for T and B cells have been shown in various models of IRI. For example, T-and B-celldeficient (Rag1 -/-and/or severe compromised immunodeficiency) mice are also protected from intestinal and myocardial IRI, and injury can be restored by independent reconstitution of either T cells or IgM (reviewed in Linfert et al. (19) ), indicating that compensatory mechanisms can contribute to IRI. A more recent study reported that hepatic IRI is independent of B cells and IgM. (17) It was shown that although Rag1 -/-mice were protected from hepatic IRI, serum transfer did not restore injury, and furthermore that Tcell-deficient mice, but not B-cell-deficient mice, were protected from hepatic IRI. These data appear to be in contradiction to the current findings. A potential explanation is that B cells can have both protective and pathogenic activities, and in this context it has been shown that specific depletion of peritoneal B-1 cells did not alter circulating levels of IgM, but reduced renal IgM binding and was protective in a model of renal IRI. On the other hand, renal IRI was increased in B-cell-deficient mice compered to WT mice. (25) The investigators attributed this apparent dual role of B cells to the production of B-1 B-cell-derived pathogenic natural IgM and its binding to postischemic mesangium versus the production of protective IL-10 by mature B cells. Regardless, anti-Annexin IV IgM antibodies exist in both mice and humans, (1, 7) and an anti-Annexin IV IgM mAb that specifically targeted the postischemic liver restored hepatic IRI in otherwise protected Rag1
-/-mice. To further address some of the confounding issues that may be associated with Rag1
-/-mice, we used a B4 scFv that, we have shown, blocks IgM binding in WT mice that have a full natural antibody repertoire, (9) and found that B4scFv was protective against hepatic IRI. Thus, in contrast to the earlier report that hepatic IRI is IgM independent, these data imply that targeting IgM and the IgM injury-sensing mechanism represents a potential therapeutic avenue for reducing hepatic IRI. Certainly, further investigation is needed to fully understand the relative contributions of T and B cells to hepatic IRI.
Although B4scFv inhibited hepatic IRI, it is interesting that it had no effect on liver injury or regeneration after PHx, even at high dose. These data imply that anti-Annexin IV antibodies are sufficient, but not necessary, for the regenerative response in a WT mouse. So, what is the cause of this discrepancy between hepatic IRI and regeneration after PHx? One possibility is that although the B4 antigen is expressed following PHx, it is not the dominant neoepitope and one or more other IgM specificities are more relevant in recognizing cellular alterations in the resected remnant liver. Compared to WT mice, B4 mAb may be able to compensate for the absence of other more relevant IgM Abs in Rag1 -/-mice. Furthermore, it is also noteworthy that there was a significantly lower uptake of 125 I-B4scFv per gram of liver following PHx compared to after IR. This could be attributed to different relative levels of insult between the two models resulting in differential or just lower levels of neoepitope expression, and consequently lower levels of B4scFv binding accounting for lack of effect of B4scFv on regeneration. In this context, IHC quantification of IgM revealed less IgM binding following PHx compared to after IR (Fig. 3) . Another possibility is that there is a compensatory mechanism in the regenerative process and molecules other than IgM are able to activate complement and stimulate regeneration. In support of this, Clark et al. (26) showed that inhibition of all traditional complement activation pathways in mice with a combined deficiency of C4 and fB still resulted in C3 cleavage and normal regeneration following PHx.
Together, the above data indicate that although complement plays a key role in both hepatic IRI and regeneration, there are some potential differences in the initiating activation event or neoepitope expression. The fact that B4 scFv limits IRI, but does not prevent regeneration, makes it a potential therapeutic candidate for use in the clinical setting of liver resection or transplantation, where the goal of therapy would be to limit IRI without hindering regeneration. In this regard, we show that B4 mAb binds to postischemic endothelium in human liver biopsy samples, and that IgM of B4 and C2 specificity is depleted from human serum of LT recipients. In summary, our data indicate that selfreactive IgM activates complement following both hepatic IRI and PHx, and plays an important role in both liver injury and regeneration. We also present evidence indicating that Annexin IV represents a postischemic neoepitope expressed in both mouse and humans following hepatic IR. These data, indicating a similar cross-species injury-specific recognition system, highlight the potential for development of translational therapies.
